胸腺肽肠溶胶囊联合人干扰素α2b阴道泡腾片治疗高危型HPV感染相关宫颈病变患者的临床研究  

Clinical trial of thymopeptide enteric-coated capsules combined with human interferonα2b vaginal effervescent tablets in the treatment of patients with high-risk HPV infection-related cervical lesions

作　　者：白雪[1] 郝淑维[1] 吕微[1] 丁雅雯[1] 杜耐一 BAI Xue;HAO Shu-wei;LÜWei;DING Ya-wen;DU Nai-yi(Department of Gynecology,Fourth Hospital of Hebei Medical University,Shijiazhuang 050000,Hebei Province,China)

机构地区：[1]河北医科大学第四医院妇科,河北石家庄050000

出　　处：《中国临床药理学杂志》2024年第21期3082-3086,共5页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察胸腺肽肠溶胶囊联合人干扰素α2b阴道泡腾片治疗高危型人乳头状瘤病毒(HPV)感染相关宫颈病变患者的临床疗效,及对T淋巴细胞亚群的影响。方法将高危型HPV感染相关宫颈病变患者按队列法分为试验组和对照组。对照组给予人干扰素α2b阴道泡腾片5×10^(5)U,每日1次,治疗2个月。试验组在对照组治疗的基础上,给予胸腺肽肠溶胶囊每次30 mg,每日3次,治疗2个月。比较2组患者的临床疗效、宫颈阴道微生态指标[阴道分泌物pH值、Nugent评分、白细胞计数]、T淋巴细胞亚群、细胞因子[白细胞介素-4(IL-4)、IL-6、IL-10、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)],并进行安全性评价。结果试验组入组70例,对照组入组72例。治疗后,试验组和对照组的总有效率分别为94.29%(66例/70例)和80.56%(58例/72例),在统计学上差异有统计学意义(P<0.05)。治疗后,试验组和对照组的阴道分泌物pH值分别为4.26±0.19和4.38±0.17,Nugent评分分别为(2.53±0.36)和(2.79±0.40)分,白细胞计数分别为(5.12±1.14)和(6.03±1.21)个,CD3^(+)分别为(69.32±8.10)%和(66.54±7.03)%,CD4^(+)分别为(37.25±5.03)%和(34.67±4.82)%,CD4^(+)/CD8^(+)分别为1.50±0.35和1.42±0.33,血清IL-4水平分别为(7.49±1.64)和(9.20±2.18)pg·mL^(-1),血清IL-6水平分别为(20.95±5.03)和(26.64±6.22)pg·mL^(-1),血清IL-10水平分别为(11.72±2.46)和(13.43±2.97)pg·mL^(-1),血清TNF-α水平分别为(16.48±3.75)和(13.25±2.03)pg·mL^(-1),血清IFN-γ水平分别为(13.35±2.11)和(10.93±2.86)pg·mL^(-1),在统计学上差异均有统计学意义(均P<0.05)。试验组的药物不良反应有恶心、发热、阴道瘙痒刺痛,对照组的药物不良反应有阴道瘙痒刺痛。试验组和对照组的总药物不良反应发生率分别为8.57%(6例/70例)和5.56%(4例/72例),在统计学上差异无统计学意义(P>0.05)。结论胸腺肽肠溶胶囊联合人干扰素α2b阴道泡腾片治疗高危型HPV感染相关�Objective To observe the therapeutic effect of thymopeptide enteric-coated capsules combined with human interferonα2b vaginal effervescent tablets in the treatment of patients with high-risk human papillomavirus(HPV)infection-related cervical lesions and the impact on T lymphocyte subsets.Methods The patients with high-risk HPV infection-related cervical lesions were divided into the treatment group and the control group according to the cohort method.The control group was given human interferonα2b vaginal effervescent tablets 5×105 U,once daily,for 2 months.On this basis,the treatment group was treated with thymopeptide enteric-coated capsules at a dose of 30 mg·time-1,three times a day,for 2 months.Therapeutic effects,cervical vaginal microecology indicators[pH values of vaginal secretions,Nugent scores and white blood cell count],T lymphocyte subsets,cytokines[interleukin-4(IL-4),IL-6,IL-10,tumor necrosis factor-α(TNF-α)and interferon-γ(IFN-γ)]were compared between the two groups,and the safety were evaluated.Results Seventy cases in the treatment group and 72 cases in the control group.After treatment,the total effective rate of the treatment group was 94.29%(66 cases/70 cases),which was higher than the control group’s 80.56%(58 cases/72 cases),the differences were statistically significant(P<0.05).After treatment,pH values of vaginal secretions in treatment group and control group were 4.26±0.19 and 4.38±0.17;Nugent scores were(2.53±0.36)and(2.79±0.40)scores;Blood cell count were 5.12±1.14 and 6.03±1.21;CD3^(+)were(69.32±8.10)%and(66.54±7.03)%;CD4^(+)were(37.25±5.03)%and(34.67±4.82)%;CD4^(+)/CD8^(+)were 1.50±0.35 and 1.42±0.33;serum IL-4 levels were(7.49±1.64)and(9.20±2.18)pg·mL^(-1);serum IL-6 levels were(20.95±5.03)and(26.64±6.22)pg·mL^(-1);serum IL-10 levels were(11.72±2.46)and(13.43±2.97)pg·mL^(-1);serum TNF-αlevels were(16.48±3.75)and(13.25±2.03)pg·mL^(-1);serum IFN-γlevels were(13.35±2.11)and(10.93±2.86)pg·mL^(-1);the differences were statistically significant(all

关 键 词：胸腺肽肠溶胶囊 宫颈病变 人乳头状瘤病毒 感染 T淋巴细胞亚群 

分 类 号：R979.1[医药卫生—药品]